Bayer sets new growth and earnings aspirations

Werner Baumann, management board chairman at German pharma and crop sciences major Bayer (BAYN: DE), is confident that the company can deliver after raising the combined peak annual sales potential of five recently launched pharmaceutical products by a third.

Indeed the group as a whole aims to achieve further growth in the coming years and is seeking higher sales and earnings in all businesses, Mr Baumann told an investor conference on Tuesday.

“We are optimistic about Bayer’s medium-term development and have therefore set ambitious aspirations," he said. “We anticipate especially significant sales and margin growth in Pharmaceuticals.